THERMO FISHER SCIENTIFIC -
Content
- Newsroom
- Press releases
- Newsroom
Low-cost kits help global public health professionals quickly identify potential outbreaks
CARLSBAD, Calif., March 9, 2022 - To support active research and surveillance of viral pathogens, including SARS-CoV-2, Thermo Fisher Scientific has launched two new reverse transcription loop-mediated isothermal amplification (RT-LAMP)-based solutions. While PCR remains the gold standard for diagnostic, lab-based testing, isothermal RT-LAMP nucleic-acid-based amplification provides a rapid and low-cost option for viral pathogen detection.
"In the global fight against COVID-19 and future infectious disease outbreaks, researchers need cost-effective, easy-to-use solutions for rapid detection of viral pathogens," said Dale Patterson, vice president and general manager of molecular biology at Thermo Fisher Scientific. "With RT-LAMP technology, researchers can accurately detect the presence of a pathogen by seeing a simple color change with the naked eye. Our new solutions enable frequent - even daily - surveillance without complex instrumentation or highly trained staff, making them ideal tools to support community surveillance in resource-constrained areas."
The Invitrogen Colorimetric ReadiLAMP Kit, SARS-CoV-2* is an off-the-shelf assay designed to provide accurate, robust detection of SARS-CoV-2 from saliva, nasal or nasopharyngeal swab samples. The kit includes two protocols: a rapid, 30-minute turnaround time for crude sample types, which reduces reagents use and costs by eliminating the need for nucleic acid isolation, or a one-hour turnaround time for increased sensitivity with purified RNA sample types.
"Thermo Fisher is committed to expanding access to solutions to aid global SARS-CoV-2 surveillance efforts as the world continues to monitor for new variants," said Ellie Mahjubi, vice president and general manager of sample preparation at Thermo Fisher Scientific. "For instance, we have introduced modified workflows that use room-temperate stable reagents to eliminate the need for cold storage. We are also gathering data on pooling samples to provide a highly affordable option for reliable population-level infectious disease monitoring that could be easily deployed anywhere in the world, including in developing countries."
For infectious disease researchers looking to research or develop their own assays for a range of applications, the Invitrogen SuperScript IV RT-LAMP Master Mix* provides fast and sensitive detection of viral pathogens, including SARS-CoV-2, measles and influenza, in as little as five minutes. The optimized master mix uses robust enzymes and is compatible with multiple methods for evaluating results, offering the flexibility to optimize assay development for a variety of RNA and DNA targets and concentrations.
To learn more about the Colorimetric ReadiLAMP Kit and SuperScript IV RT-LAMP Master Mix, visit thermofisher.com/rtlamp.
*For research use only. Not for us in diagnostic procedures.
The Invitrogen Colorimetric ReadiLAMP Kit, SARS-CoV-2 is an off-the-shelf assay designed to provide accurate, robust detection of SARS-CoV-2 from saliva, nasal or nasopharyngeal swab samples.
The Invitrogen SuperScript IV RT-LAMP Master Mix provides fast and sensitive detection of viral pathogens, including SARS-CoV-2, measles and influenza, in as little as five minutes.
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Media contact information:
Mauricio Minotta
760-805-5266
mauricio.minotta@thermofisher.com
Jen Heady
413-237-5141
jheady@greenough.biz
SOURCE Thermo Fisher Scientific
If you have any questions regarding this Press Release, please email us at media.relations@thermofisher.com.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Thermo Fisher Scientific Inc. published this content on 09 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 March 2022 13:41:03 UTC.
